Compare Nasdaq Inc (NDAQ) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Stryker Corporation — how do they compare? Nasdaq Inc trades at $89.8 (market cap $51.96B), while Stryker Corporation trades at $319.04 (market cap $122.35B). The key difference: Stryker Corporation is far larger — about 2.4× Nasdaq Inc's market cap, and Nasdaq Inc pays the higher dividend (1.22%). Which is the better fit depends on your goals.
| NDAQ | SYK | |
|---|---|---|
Market Cap | $51.96B | $122.35B |
Sector | Financials | Technology |
52-Week High | $100.98 | $403.53 |
52-Week Low | $76.85 | $282.58 |
Enterprise Value | $59.02B | $134.10B |
Dividend Yield | 1.22% | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $90.24, down 1.53% today, with a bullish technical signal from moving averages and a consensus analyst price target of $107.00. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.96 exceeding expectations, and maintains robust profitability with a net income margin of 23.03%. Recent news highlights strategic growth, including the acquisition of Nasdaq Fund Secondaries by NPM, expanding its platform beyond direct company shares.
The outlook for NDAQ is positive, supported by organic revenue growth and strategic acquisitions, though risks include market volatility and execution challenges. With 61.11% of analysts rating it a buy and a price target implying ~19% upside, the stock presents a growth opportunity for investors focused on financial infrastructure expansion, balanced by monitoring debt levels and competitive pressures.
Stryker (SYK) trades at $319.14, down 0.23% with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust margins. Recent news highlights Mako RPS launch expansion in robotic surgery, while Q1 2026 earnings missed expectations due to a temporary cyber disruption, though full-year guidance remains unchanged.
Outlook remains positive with 74% analyst buy ratings and a $388.44 consensus price target implying 22% upside. Key risks include competitive pressures and execution challenges from recent cybersecurity issues. The stock presents a growth opportunity in med-tech innovation, trading below historical valuation multiples with healthy cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
